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Abstract
Introduction: Gastro-intestinal stromal tumours are the most common mesenchymal tumours of the gastro-
intestinal tract. This case report highlights the necessity of early surgical intervention in such cases to avoid
mortality due to rebleeding and to raise the awareness of rare causes of upper gastrointestinal bleed and their
management.
Case presentation: A 61-year-old male presented to the accident and emergency department with a one-day
history of haemetemesis with coffee ground vomiting. After initial resuscitation, he underwent upper
gastrointestinal endoscopy under sedation which demonstrated a large, bleeding, gastric mass with a central crater
along the greater curvature of the stomach. A partial gastrectomy was performed taking a wedge of the stomach
with clearance from the tumour, with no signs of extraperitoneal disease.
Conclusion: Early surgical intervention, either open or laparoscopic resection, is the treatment of choice to prevent
rebleeds. In general, complete surgical resection is accomplished in 40-60% of all gastro-intestinal stromal tumours
patients, and in >70% of those with primary non- metastatic gastro-intestinal stromal tumour. In our case we had
completely excised the tumour. Following surgery, all patients must be referred to centres which have more
experience in treating gastro-intestinal stromal tumours. Imatinib is proven to be the first effective systemic therapy
in cases of unresectable or metastatic disease. All gastro-intestinal stromal tumours have the potential for
aggressive behaviour with the risk being estimated from tumour size and mitotic count.
Introduction
Gastro-intestinal stromal tumours (GIST) are the most
common mesenchymal tumours of the gastro-intestinal
tract (GI). They account for approximately 0.1 to 3% of
all GI neoplasms. Usually, GISTs present in middle age
people with a peak age of presentation at 58 yrs, affecting
males and females equally. They rarely occur in children
or young adults, but when they do, an association with
neurofibromatosis and Carney’s triad (gastric stromal
tumor, extra adrenal paraganglioma and pulmonary chor-
doma) has been noted [1]. Most frequently, they are soli-
tary, well circumscribed tumors with a pseudocapsule.
They arise from embryological mesoderm of the GI tract
and were initially thought to be smooth muscle tumours.
They are however resistant to chemotherapeutics and
have morphological and immunohistochemical features
dissimilar to smooth muscle. About 40-70% occur in the
stomach, 20-40% in the small intestine, and 5-15% else
where in the GI tract (oesophagus, rectum, omentum,
peritoneum). Upper GI bleeding is the commonest pre-
sentation of GISTS- varying between 50-100% depending
on the case series. However, GISTs as a cause of upper
GI bleeding is rare. They can also present with abdominal
pain, dyspepsia and vomiting or incidental findings dur-
ing endoscopy, imaging or surgery.
The clinical presentation o fG I S T si sv a r i a b l e .I t
depends on the size and organ involvement. Gastric
GISTs usually present with vague abdominal pain, dys-
pepsia, and vomiting. They rarely present with second-
ary complications such as upper GI bleeding and
perforation. Asymptomatic GISTs are found incidentally
during surgery, endoscopy or CT scan for other
conditions.
This case report highlights the necessity of early surgi-
cal intervention in such cases to avoid mortality due to
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upper GI bleed and their management.
Case presentation
A 61-year-old British Caucasian male presented to the
Accident and Emergency with a one-day history of hae-
metemesis with coffee ground vomiting. He was an ex-
alcoholic with no history of chronic liver disease or pep-
tic ulceration. After initial resuscitation, he underwent
upper GI endoscopy under sedation which demonstrated
large clots in the stomach (Figure 1). Repeat upper GI
endoscopy was therefore performed urgently under gen-
eral anaesthesia with a therapeutic endoscope. A large,
bleeding, gastric mass with a central crater was identi-
fied along the greater curvature of the stomach after the
aspiration of clots. Bleeding was then controlled with
the use of adrenaline injection and argon plasma
coagulation. He needed a blood transfusion following
the procedure. Following this, he had a CT scan which
showed a well-defined, dumb-bell shaped 6 cm mass
arising from the greater curvature of stomach with most
of the mass being extra luminal (Figure 2). There was
no evidence of distant lesions. He had another episode
of haematemesis 48 hours after the therapeutic endo-
scopy necessitating 5 units of blood transfusion. It was
therefore decided to proceed with an upper GI endo-
scopy (Figure 3) with a view to proceed to immediate
laparotomy and resect the tumor, which was the source
of the rebleeding.
At laparotomy, the tumour was identified on the
greater curvature with no evidence of liver, peritoneal,
omental or lymph nodal lesions. A partial gastrectomy
was performed taking a wedge of the stomach with
clearance from the tumour (Figure 4).
Figure 1 Gastric mass with a bleeding vessel in a central crater.
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Page 2 of 7Figure 2 CT scan revealing 6 cm mass with no evidence of extraperitoneal spread.
Figure 3 Bleeding vessel after control.
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Page 3 of 7The histology report showed a 7 cm (Figure 5), well
circumscribed, non-encapsulated tumour within submu-
cosa and muscularis propria. On microscopy the tumour
was composed of spindle cells with no significant
nuclear pleomorphism (Figure 6). The mitotic count
w a sl o w( l e s st h a n5m i t o s i sp e r5 0H P F )w i t hn oe v i -
dence of dysplasia or malignancy of overlying gastric
mucosa (Figure 7). Immunostaining of the tumor cells
were strongly positive for CD117 and negative for S100,
desmin, smooth muscle, and actin (Figure 8). The above
features strongly suggested the diagnosis of GIST. He
did well following surgery. Subsequently he was entered
into a randomised controlled trial for Glivac.
Discussion
The incidence of GISTs has increased in the last few
years due to better detection as all mesencymal tumours
are now being tested for CD117. CD117 (Kit protein) is
the product of c-kit proto-oncogene, located on chro-
mosome 4q11-21. This protein is a tyrosine kinase
growth factor receptor present in 90% of GIST cells.
Mutation of kit proto-oncogene results in a CD117
receptor that is constitutively stimulated without the
presence of the stem-cell growth factor [2]. Some of the
GISTs that lack the kit mutation appear to have a muta-
tion in another Class III protein kinase gene that
encodes the platelet-derived growth factor [3]. It is now
believed that these tumours arise either from stem cells
that differentiate towards interstitial cells of Cajal (these
cells form part of the myenteric plexus in the gastroin-
testinal tract and regulate peristalsis) or directly from
interstitial cells of Cajal and not from smooth muscle
cells [4]. The annual incidence of GIST is 15 per million
and the prevalence is approximately 130 per million in
western populations.
GIST is an unusual cause of Upper GI bleed, and has
a high propensity to rebleed. These bleeding tumours
need to be investigated urgently as an inpatient rather
than as an outpatient. Early surgical intervention, either
open or laparoscopic resection, is the treatment of
choice to prevent rebleeds. In general, complete surgical
r e s e c t i o ni sa c c o m p l i s h e di n4 0 - 6 0 %o fa l lG I S T
patients, and in >70% of those with primary non- meta-
static GIST [5]. In our case we had completely excised
the tumour.
GISTs exhibit a highly variable behaviour after resec-
tion of the primary tumour. These patients need to be
followed up on a long term basis as local recurrence and
metastases can occur many years after surgery. These
tumours spread by the haematogenous route predomi-
nantly to the liver. Lymph node involvement in very rare
and therefore lymphadenectomy is not routinely indi-
cated [6]. In general, local recurrence or metastases
develop in approximately 50% of patients who had poten-
tially curative operation [7]. The median disease specific
survival for patients with primary GIST is approximately
5 years [8]. The two most important tumor factors for
local recurrence and metastasis are tumour size and
Figure 4 Intra-operative image showing GIST before resection.
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Page 4 of 7Figure 6 Histopathology specimen highlighting low mitotic activity.
Figure 5 Highlighting the GIST specimen once removed post operatively measuring 6 cm.
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Page 5 of 7mitotic rate (size >5 cms and mitosis >5 per 50 HPF
increases the risk) [9]. Other prognostic factors are com-
pleteness of resection, age, and tumor location. Gastric
GISTs have a lower risk of tumor recurrence than oeso-
phageal, small bowel or large bowel GISTs.
Before the Imatnib era surgical resection was the only
option available as GIST are highly resistant to che-
motherapy and radiotherapy. The 5 year survival rate
was 35-65% following complete resection and the medial
survival rate was 10-20 months for unresectable disease.
The introduction of Imatinib mesylate, a tyrosine kinase
inhibitor, has dramatically improved the outcomes of
treatment. It had demonstrated in clinical trials a signifi-
cant decrease in tumour size rendering initially inoper-
able tumour resectable [10]. In phase I and II trials, Van
Ooseterom et al [10] and Demetri et al, [11] saw a
Figure 7 Specimen showing spindle cells with no significant nuclear pleomorphism.
Figure 8 Showes immunostaining of the tumor cells which were strongly positive for CD117 and negative for S100, desmin, smooth
muscle, and actin.
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burden) in 79% of patients, stable disease in 28%, and
progressive disease in 13%. The overall survival rate
after 1 year was 88%, although the median duration of
survival is yet to be defined. Currently imatinib is
approved only for the treatment of advanced disease.
The recommended starting dose is 400-600 mgs. Recent
European phase III trails have demonstrated that 400
mgs twice daily significantly prolonged progression free
survival. It is well tolerated orally with minor side effects
like rash, nausea, diarrhoea, muscle cramps, periorbital
and peripheral oedema. Myelosuppression was rare. The
duration of treatment has not yet been defined. The
phase II trials of Radiation and oncology Group study
S-0132 recommends imatinib for 2 years [12].
The current recommendations in management of
GIST are as follows; [13]
￿ For operable GISTs, perform surgery first followed
by adjuvant therapy with Imatinib in high risk
patients (size > 5 cms, mitotic rate >5 per 50 HPF,
incomplete resection, tumour spillage).
￿ For marginally resectable GIST or in case of inop-
erable recurrent or metastatic GIST, consider neoad-
juvant therapy with Imatinib followed by surgical
resection.
￿ For intermediate risk GIST (size < 5 cms and 6-10
mitosis per 50 HPF, or 5-10 cms and, 5 mitosis per
50 HPF), the role of Imatinib as an adjuvant therapy
is still debatable.
Follow up guidelines following resection of GIST are
yet to be defined for low risk, intermediate risk and
high risk GIST. According to National Comprehensive
Cancer Network practice guidelines all completely
resected GIST are followed in clinic with CT scan every
3-6 month for the first 5 years and then annually. Less
surveillance is acceptable for low risk patients [14].
Conclusion
GIST is an unusual cause of upper GI bleeding. Early sur-
gical intervention is the treatment of choice to prevent
rebleeds. All suspected mesenchymal tumors of GI
should be tested for CD117 by an experienced histo-
pathologist. Following surgery, all patients must be
referred to centres which have more experience in treat-
ing GIST. Imatinib has proven to be the first effective
systemic therapy in cases of unresectable or metastatic
disease. In case of operable GIST, Imatinib is indicated as
an adjuvant therapy in high risk patients. All GISTS have
the potential for aggressive behaviour, the risk being esti-
mated from tumour size and mitotic count [15].
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